Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

IF 13.4 1区医学 Q1 HEMATOLOGY

Leukemia Pub Date : 2025-10-02 DOI:10.1038/s41375-025-02778-1

Alessandra Tedeschi,Anna Maria Frustaci,Pierantonio Menna,Giorgio Minotti

引用次数: 0

查看原文本刊更多论文

用venetoclax和Bruton酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病的固定疗程：伊鲁替尼和阿卡拉布替尼之间的差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia 医学-血液学

CiteScore

18.10

自引率

3.50%

发文量

270

审稿时长

3-6 weeks

期刊介绍： Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues